IL-2 not checked
Iovance Biotherapeutics, Inc. · Interleukin-2
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001”In the company’s words, NCT04155710 on ClinicalTrials.gov
- Main trialPhase 1
- “This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.”In the company’s words, NCT04155710 on ClinicalTrials.gov
- Other names
- Interleukin-2
Other drugs for Chronic Lymphocytic Leukemia
- SonrotoclaxBeOne Medicines (BeiGene) · Phase 3
- VenetoclaxAbbVie · Phase 3
- ZanubrutinibBeOne Medicines (BeiGene) · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- TacabrutidegBeOne Medicines (BeiGene) · Phase 3
- AcalabrutinibAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 11 Nov 2024 | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026